- Home
- SXTP vs AZTR Comparison
SXTP vs AZTR Comparison
Compare SXTP & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- AZTR
- Stock Information
- Founded
- SXTP 2010
- AZTR 2014
- Country
- SXTP United States
- AZTR United States
- Employees
- SXTP N/A
- AZTR N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- AZTR Health Care
- Exchange
- SXTP Nasdaq
- AZTR Nasdaq
- Market Cap
- SXTP 3.4M
- AZTR 3.7M
- IPO Year
- SXTP 2023
- AZTR 2023
- Fundamental
- Price
- SXTP $1.39
- AZTR $0.82
- Analyst Decision
- SXTP Buy
- AZTR
- Analyst Count
- SXTP 2
- AZTR 0
- Target Price
- SXTP $3.00
- AZTR N/A
- AVG Volume (30 Days)
- SXTP 77.5K
- AZTR 7.5M
- Earning Date
- SXTP 08-13-2025
- AZTR 08-11-2025
- Dividend Yield
- SXTP N/A
- AZTR N/A
- EPS Growth
- SXTP N/A
- AZTR N/A
- EPS
- SXTP N/A
- AZTR N/A
- Revenue
- SXTP $984,494.00
- AZTR N/A
- Revenue This Year
- SXTP $81.41
- AZTR N/A
- Revenue Next Year
- SXTP $95.63
- AZTR N/A
- P/E Ratio
- SXTP N/A
- AZTR N/A
- Revenue Growth
- SXTP 128.70
- AZTR N/A
- 52 Week Low
- SXTP $1.22
- AZTR $0.70
- 52 Week High
- SXTP $12.45
- AZTR $4.45
- Technical
- Relative Strength Index (RSI)
- SXTP 46.47
- AZTR 38.92
- Support Level
- SXTP $1.33
- AZTR $0.74
- Resistance Level
- SXTP $1.45
- AZTR $1.09
- Average True Range (ATR)
- SXTP 0.08
- AZTR 0.11
- MACD
- SXTP 0.02
- AZTR 0.01
- Stochastic Oscillator
- SXTP 54.20
- AZTR 17.42
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.